Each formulation has been tested for stability under specific conditions, and the manufacturer or compounding pharmacy assigns storage guidelines based on those tests
After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )
Supplementation of the diet with high-viscosity beta-glucan results in enrichment for lactobacilli in the rat cecum
Cagrilintide showed similar directional improvements, though the magnitude was generally proportional to the degree of weight loss rather than suggesting independent cardiovascular effects
Systemic: A Comparison for Researchers To help clarify the decision-making process for your research design, we've put together a simple comparison
Insomnia can be either: Acute Insomnia: lasting a few days or weeks Chronic Insomnia: lasting months to years
